Norstella’s Post

Explore the forefront of pharmaceutical innovation with Norstella’s June roundup, featuring cutting-edge insights from industry trailblazers and learn about the latest news and updates from our brands. Check out the links below. 👇 Norstella announced a new strategic partnership with Atropos Health, the pioneer in translating real-world clinical data into high-quality, personalized, real-world evidence for care. Read about the benefits for Panalgo and Citeline customers: https://ow.ly/PgZO50SsStC Citeline Regulatory's TrialScope Disclose has been the leader in helping clinical trial sponsors prepare their studies for public disclosure for over a decade. With the addition of the Core Data platform, it continues to provide cutting-edge disclosure technology to enable seamless regulatory compliance. Learn more: https://ow.ly/uvA750SsStG Are you ready to look at the pharma landscape through a long-range lens? Evaluate Ltd has just released new forecasts out to 2030. Register for the World Preview Webinar 2024 Pharma’s Growth Boost: https://ow.ly/Sylo50SsStF Do you need a primer on market access? In this free ebook from MMIT (Managed Markets Insight & Technology) for pharma, you can learn how to understand and influence payer policies, improve coverage and communicate with HCPs. https://ow.ly/eSgf50SsStJ Understanding open and closed claims is critical. In this eBook, Panalgo's Executive Director of Solutions, Margaret (Meg) Richards, PhD, MPH, uncovers the nuances of open vs. closed claims: https://ow.ly/jP8v50SsStI The Dedham Group stands as the premier pharmaceutical consultancy firm, renowned for its expertise in crafting, executing, and overseeing Patient Support Programs. Learn about The Dedham Group’s customized solutions that drive success: https://ow.ly/c20450SsStE Follow our brands to stay up with the latest news, insights, and updates! #Pipeline2Patient #FollowNorstella

Partnering with patients to develop clinical trials and medicines that delivers the most relevant clinical outcomes and supports sustainable healthcare systems.    At the Measuring Patient Engagement Summit, I will discuss our Patient Engagement Impact Measurement Framework that we co-created with a patient council. A standardized approach across the pharmaceutical industry that would support evidence generation and best practice sharing, so join this session to see how you could adapt and apply this approach to your own work. I will: - Introduce the framework and how it is connected to strategy across the medicines lifecycle  - Summarise the challenges and learnings we’e had so far from developing the framework and implementing the metrics - Give examples for key patient engagement activities such as patient life experience; patient-focused drug development, patient support programs.   Only together we will make patient voice basics of medicine lifecycle, see you there!

Ready to transform managed markets with transparency, efficiency, and innovation? Let's dive in! Discover how an N-sided marketplace can revolutionize the life sciences industry! Pharmatching is on the path to become the ideal N-sided marketplace for the life sciences industry, connecting pharmaceutical companies, payers, providers, and patients. By facilitating transparent and efficient interactions, Pharmatching enhances collaboration, streamlines negotiations, and supports informed decision-making, ultimately driving innovation and better health outcomes. Join Pharmatching and be a part of the future of managed markets!

🚀 The Power of Early Evidence in Market Access 🚀 🌟 Did you know the average cost of developing a new drug is a staggering $1.3 billion? Despite this investment, many new treatments struggle to achieve commercial success due to stringent evidentiary requirements from healthcare payers. 🔍 Our latest blog post delves into how evidence generation is crucial for overcoming these hurdles. Discover how an early evidence strategy, tailored to the diverse needs of regulators, payers, clinicians and patients, can pave the way for successful market access. Key insights include: ·       🔗 The disconnect between regulatory approval and successful market access ·       🎯 The importance of aligning clinical trial design with HTA and payer requirements ·       📊 Strategies for comprehensive evidence generation to support reimbursement 📖 Read the blog now via the link in the comments. Stay tuned for Part 2, where we explore the four pillars of an effective early evidence generation strategy! Author: Evangelos Vasileios Papastergios #MarketAccess #HTA #Pharmaceuticals #HEOR #RealWorldEvidence

Explore the forefront of pharmaceutical innovation with Norstella’s May roundup, featuring cutting-edge insights from industry trailblazers and the latest breakthroughs in patient diversity, clinical research, and market analytics. Check out the links below. 👇 Clinical development success rates have steadily been falling over the last decade. This drop is both a concern and inevitable as competition intensifies and the barriers to market entry become higher. Click to read the breakdown on the Norstella blog: https://ow.ly/RhFu50S47o9 Accelerate your success with Citeline Consulting & Analytics. Using a global lens, Citeline's consultants use deep domain expertise, market-leading insights, and real-world data solutions to optimize your strategy for successful business outcomes. Learn more: https://ow.ly/eogZ50S47ob Explore why #radiopharmaceuticals are captivating the industry. In this ebook, Evaluate Ltd discusses the latest science, dealmaking, and commercial opportunities in the landscape, highlighting some of its most intriguing players. Download now: https://ow.ly/FrEC50S47oe Missed Asembia's AXS24 Summit? MMIT (Managed Markets Insight & Technology) has you covered! Check out this blog post for essential insights on personalized medicine, cost management, and maximizing drug lifecycles: https://ow.ly/TLRM50S47oa ISPOR Annual 2024 was held in Atlanta, and the Congress did not disappoint. Panalgo's Margaret (Meg) Richards reflects on #ISPORAnnual in this blog, including a discussion on 'whole health' and shifting from patient-centered care to person-centered care. Read it now: https://ow.ly/Yo5n50S47oc The Dedham Group merges innovative strategies with tailored data solutions to transform businesses. Through clear strategic planning and collaborative partnerships, they boost performance, solidify market presence, and generate substantial value. Learn more: https://ow.ly/gzex50S47o8 Follow our brands to stay up with the latest news, insights, and updates. #Pipeline2Patient #FollowNorstella

A really well-thought-out piece by my friend and colleague Ella Balasa. She's hit the nail on the head on many fronts. A lot of supporting and counter points and questions come to mind: 1. 🐌 In any slow-moving industry, it takes about a decade of conversations before meaningful adoption and possibly another decade before meaningful outcomes analysis. Think publishing and open access, for example. When I worked in publishing, every industry conference for over a decade had a panel on the future of open access. And I wondered what next and when. It's debatable where the pharma/healthcare industry currently stands on this idea-to-adoption-to-measurement timeline for patient engagement. Ella argues that we are past the conversation and closer to the implementation and measurement timepoints. But my question is how many pharma and medical conferences, apart from those that have "Patients as Partners" in their name, even have patients on the speaker agenda or as a category in their registration forms? 2. 🪟I love Ella's point about the need for transparency with patients regarding the commercial value and profitability of patient-centric initiatives. This is potentially controversial because the truth is there are MASSIVE numbers of patients who see pharma as entirely profit-making and are suspicious of the industry in general. On the contrary, there are also increasing numbers of reasonable business-savvy patients who understand the massive investments pumped into medicine development and the need for profitability. Which of these categories of patients are more likely to be attending medical conferences and reading these publications? Why not truly partner and brainstorm brass tacks with these more broad-minded patients who have the power to influence mindsets within their extended networks of patients? 3. 🛣️ While Ella's ask is for pharma companies at more advanced stages of patient engagement, I'd expand it to include those at all stages: - If you don't yet have patient representation in your conferences and publications, you're already 5 years behind. Step on it! - If you have succeeded in building out your patient engagement strategy, start implementing it and sharing best practices. - If you have been intrinsically implementing patient engagement at various levels, start measuring your outcomes and discussing them transparently with patients. - If you don't know how to involve patients, ask us! #patientengagement #patientcentricity #patientinvolvement #patientadvocates #healthcare #pharma

As I learn more about clinical trials and patient engagement initiatives for my research, it is very refreshing to read articles that push for a data-driven approach to selecting patient engagement initiatives, as this article from Ella Balasa does! We will hopefully get to read more case studies on this in the upcoming years! #patientengagement #clinicaltrials

🌟 Exciting insights from our CEO Jenny Ousbey who spoke at the Patient Centricity & Collaboration World Congress earlier this week! 🌍 At the event, Emma Sutcliffe spearheaded a theme of #noexcuses for progress. In that spirit, here are Jenny's six compelling reasons why patient advocacy and engagement are essential for pharmaceutical companies: 1️⃣ Patient engagement boosts participation in clinical trials and improves medicine adherence. 2️⃣ 81% of FDA approvals in 2019 relied on relevant patient experience data. 3️⃣ Engaging patients pre-launch can trim product time to market by 2.5 years. 4️⃣ 90% of doctors equate patient engagement with data, emphasizing the need for further progress. 5️⃣ Investors are increasingly prioritizing patient centricity and engagement in discussions with executives. 6️⃣ Yet, only a few companies have a Chief Patient Officer on their leadership team, indicating room for improvement. As Leonard Kish noted, patient engagement is the blockbuster drug of the century. Let's rally behind it! 💪 Join the movement by participating in the Patient Partnership Index at https://lnkd.in/esSzZQMc. The Association of the British Pharmaceutical Industry (ABPI) Healthcare Communications Association (HCA) #PatientCentricity #Pharmaceuticals #NoExcuses #Leadership

Does #PatientEngagment have an impact? For patients, for companies and for the healthcare system. And which opportunities make the biggest difference? This is one of biggest questions I wanted to answer when joining Novartis, to demonstrate the value of engaging with patients and to help the industry focus on the opportunities for engagement that make the most difference. Involvement of patients is not enough without meaningful impact, and I am pleased to announce that Beyza Klein, Marc Boutin and others have been working on a co-created framework to measure and demonstrate the impact of patient engagement (over the past two years) - which Beyza will be presenting this week in Boston (with more publications to follow). Most of the discussion to date has focused on individual examples of where involvement has made an impact, rather than regular reporting of inputs/outputs/outcomes/impact. A standardised approach to measurement of Patient Engagement is needed across the industry. This framework has been designed to be applicable and adaptable to different organisations and stages of the medicines lifecycle. But this cannot be done by Novartis alone, and I hope that others can continue to build on this work - and share any feedback or learnings to help further improve this important initiative. Michaela Dinboeck Shreeram Aradhye Ruchira Glaser, MD, MS Clin Epi Biostatistics

A game-changer for participant experience in clinical trials? Novartis's Patient Engagement Impact Measurement Framework has the potential to be a significant breakthrough. Why? Standardised metrics can ensure participants, especially children in paediatric trials, have their voices heard and experiences valued throughout the research process. This framework offers the potential for: Clearer understanding of participant needs - Consistent data allows researchers to tailor trials to better meet participants' specific requirements. Improved communication and collaboration - Standardised metrics facilitate clear communication between researchers, patients, and caregivers, enhancing the overall experience. Empowerment for young participants - Children's voices are often underrepresented, that's why we do what we do here at Little Journey. This framework ensures their experiences are accurately captured and valued. For companies like ours, specialising in paediatric trials, this standardised approach is vital. It allows us to continuously improve the patient journey for young participants. #PatientEngagement #ClinicalTrials #Paediatrics